Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis

Singh, Rohan Bir; Parmar, Uday Pratap Singh; Cho, Wonkyung; Ichhpujani, Parul

doi:10.3390/vaccines10101630

Cited by 10 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past, ocular adverse events such as uveitis, keratitis, and optic neuritis have been reported after vaccinations. 9,[16][17][18] Herpetic eye disease is the most common cause of infectious and inflammatory keratitis, primarily caused by HSV and VZV. [19][20][21] The causative viruses typically infect humans during the early years and remain dormant for decades in the neurons of dorsal root ganglia, cranial nerve ganglia, and autonomic ganglia until reactivation due to trauma, stress-related triggers or due to an immune compromised state.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis

Singh

Parmar

Ichhpujani

et al. 2023

Cornea

Self Cite

View full text Add to dashboard Cite

Purpose:The aim of this study was to evaluate the cases of herpes simplex and zoster ophthalmicus after SARS-CoV-2 vaccination and assess the clinical presentations in patients.Methods:A retrospective analysis of cases reported to the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS) between December 11, 2020, and July 1, 2022. Patients diagnosed with herpes simplex ophthalmicus (HSO) and herpes zoster ophthalmicus (HZO) after vaccination with BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and Ad26.COV2.S (Janssen) were included in the study. We performed a descriptive analysis of patient demographics, history, and ophthalmic and systemic clinical presentations. The correlations between vaccine type and continuous variables were assessed by the one-way analysis of variance test. In addition, we used the Pearson χ2 test to assess the association between 3 vaccines and categorical variables. A post hoc analysis was performed between HSO and HZO onset intervals after vaccination, dose, and vaccine type. The 30-day risk analysis was also performed for HSO and HZO onset postvaccination using the reverse Kaplan–Meier analysis.Results:A total of 1180 cases of HZO (983, 83.30%) and HSO (180, 15.25%) were reported. The mean age of patients with HZO and HSO was 59.02 ± 19.05 and 52.68 ± 17.83 years, respectively. Most of the cases of HZO (795, 80.87%) and HSO (131, 72.78%) were reported in patients who received BNT162b2. In the cohort, 63.28% and 65.56% diagnosed with HZO and HSO were women. About one third of HZO (36.52%) and HSO (35.56%) cases were reported after the first dose. More than half of the cases of HZO (61.34%) and HSO (64.45%) were reported within the first 2 weeks after vaccination. The estimated crude reporting rate (per million doses) in the United States was 0.25, 0.22, and 0.47 for BNT162b2, mRNA-1273, and Ad26.COV2.S, respectively. The onset interval for HZO was significantly shorter in patients who received BNT162b2 (20.51 ± 56.20 days, P = 0.030) compared with patients who received mRNA-1273 (36.56 ± 108.67 days) and Ad26.COV2.S (39.66 ± 60.15 days) vaccines. The 30-day risk analysis showed a significantly higher risk of HZO after BNT162b2 than the other 2 vaccines (P = 0.011).Conclusions:The low crude reporting rate suggests that HZO and HSO after SARS-CoV-2 vaccination occur rarely. This study provides insights into the possible temporal association between reported HSO and HZO after SARS-CoV-2 vaccines; however, further investigations are required to delineate the possible underlying immunological mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In the past, ocular adverse events such as uveitis, keratitis, and optic neuritis have been reported after vaccinations. 9,16–18…”

Section: Discussionmentioning

confidence: 99%

Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis

Singh

Parmar

Ichhpujani

et al. 2023

Cornea

Self Cite

View full text Add to dashboard Cite

show abstract

“…A recent publication [ 28 ] assessed the risk of vaccine-associated uveitis (VAU) following SARS-CoV-2 vaccination using the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Events Reporting System (VAERS). The study found an estimated crude reporting rate (per million doses) of 0.57, 0.44, and 0.35 for BNT162b2, mRNA-1273, and Ad26.COV2.S, respectively, i.e., the three vaccines rarely caused VAU.…”

Section: Discussionmentioning

confidence: 99%

Posterior ocular manifestations following BNT162b2 mRNA COVID-19 vaccine: a case series

2022

View full text Add to dashboard Cite

Purpose To report the occurrence of posterior ocular adverse events following the administration of the BNT162b2 mRNA vaccine against SARS-CoV-2. Methods A retrospective consecutive case series, in which the medical files of patients presenting with ocular adverse events within 30 days of the vaccine inoculation, were analyzed. Results Four patients (2 females) were included in the study. The diagnoses included: posterior scleritis, paracentral acute middle maculopathy, herpes panuveitis, and Vogt–Koyanagi–Harada (VKH)-like uveitis. Three of the patients had no relevant ocular history, but the patient who developed scleritis was in remission without medical therapy for four years, until the flare-up, which occurred one day after the vaccine. All patients improved with treatment. Conclusion Though a causal relationship cannot be definitively established, the temporal relationship suggests a possible link between the COVID-19 vaccine and the posterior ocular complications. The benefits of vaccination clearly outweigh the potential adverse effects; however, ophthalmologists should be aware of the potential for vaccine-associated uveitis.

show abstract

“…Since the commencement of the most extensive global vaccination efforts, few studies have evaluated the safety concern of ophthalmic adverse events following SARS-CoV2 vaccination using the VAERS database. [14][15][16] Here, we assess the cases of VAR following the administration of the three United States Food and Drugs Administration (FDA) authorized COVID-19 vaccines (BNT162b2, mRNA-1273 and Ad26.COV2.S) reported to the VAERS from all over the world. In addition, we evaluate the demographics, association with the type of corneal transplantation, average VAR onset interval post-vaccination and clinical characteristics observed in patients.…”

Section: Clinical Sciencementioning

confidence: 99%

Vaccine-associated corneal graft rejection following SARS-CoV-2 vaccination: a CDC-VAERS database analysis

Singh

Parmar

et al. 2022

Br J Ophthalmol

Self Cite

View full text Add to dashboard Cite

PurposeTo evaluate the cases of corneal graft rejection following SARS-CoV-2 vaccination reported to Centers for Disease Control and Prevention Vaccine Adverse Event Reporting System.MethodsA descriptive analysis of the demographics, clinical history and presentation was performed. We evaluated the correlation between the vaccines and duration of vaccine-associated graft rejection (VAR) onset following vaccination using a one-way analysis of variance test. A post hoc analysis was performed between VAR onset-interval following vaccination dose and vaccine type. Finally, a 30-day cumulative incidence analysis was performed to assess the risk of VAR in short term following different doses, vaccines and type of corneal transplantation.ResultsA total of 55 eyes of 46 patients were diagnosed with VAR following vaccination with BNT162b2 (73.91%) and mRNA-1273 (26.09%). The mean age of the patients was 62.76±15.83 years, and 28 (60.87%) were female. The patients diagnosed with VAR had undergone penetrating keratoplasty (61.82%), Descemet membrane endothelial keratoplasty (12.73%), descemet stripping endothelial keratoplasty (18.18%), anterior lamellar keratoplasty (3.64%) and corneal limbal allograft transplantation (1.82%). The mean time for VAR since penetrating and endothelial keratoplasty was 8.42±9.23 years and 4.18±4.40 years, respectively. 45.65% of the cases of VAR were reported after the second dose of vaccine. The duration of VAR onset was significantly shorter after the second dose compared with the first and booster doses (p=0.0165) and in patients who underwent endothelial keratoplasty compared with penetrating keratoplasty (p=0.041).ConclusionsThis study outlines a possible temporal relationship between corneal graft rejection and SARS-CoV-2 vaccination. An earlier onset of VAR was observed in patients who had a history of endothelial keratoplasty and following the second dose of vaccination.

show abstract

Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis

Cited by 10 publications

References 25 publications

Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis

Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis

Posterior ocular manifestations following BNT162b2 mRNA COVID-19 vaccine: a case series

Vaccine-associated corneal graft rejection following SARS-CoV-2 vaccination: a CDC-VAERS database analysis

Contact Info

Product

Resources

About